INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
We have developed twelve tests for COVID-19 globally. We have molecular and antigen tests that help detect an active infection of COVID-19, as well as serology tests that help detect antibodies. Our first molecular test is used on our lab-based molecular instrument, m2000. Many of these instruments are already located in hospital and academic medical center labs where patients go for care. For more information on m2000, check out this article: https://abbo.tt/2U1WMiU
We also have a molecular test for our Alinity m system under the FDA's Emergency Use Authorization. For more information on Alinity m, check out this news release: https://abbo.tt/2zrt52N
Our rapid, molecular point-of-care test detects COVID-19 in 13 minutes or less. This test is used on our ID NOW instrument. For more information on ID NOW check out this article: https://abbo.tt/2UT36cN
Our rapid antigen test, BinaxNOW™ COVID-19 Ag Card, Home Test and Self Test all provide results in 15 minutes. The test does not need any additional equipment. It can be used in three different ways. It can be self-administered at home, performed by healthcare professionals at the point-of-care, or it can be used at home with a virtually guided collection and testing process in partnership with eMed™, an online digital health service, making it an important tool to diagnose COVID-19. All three versions of the test pair with our optional mobile app for iPhone and Android devices, NAVICATM. The first-of-its-kind app, available at no charge, allows people who test negative to get a temporary digital health pass that's renewed each time the person has a negative test. Results are encrypted and available only to you and those you choose to share them with. Organizations like employers and schools have the option to use the app to view and verify the information on a mobile device to facilitate safer entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing.
You can find more information on BinaxNOW COVID-19 Ag Card and NAVICA here.
Abbott also developed separate lab-based serology blood tests to detect IgM and IgG antibodies that identify if a person has been previously exposed to the virus that causes COVID. The tests are available on our ARCHITECT and Alinity i systems.
For more information on our ARCHITECT antibody test, check out this article: https://abbo.tt/3abd0eq For more information on the Alinity i system, check out this news release: https://abbo.tt/2SWCvtU For more information on our IgM antibody test, check out this news release: https://abbott.mediaroom.com/2020-10-12-Abbott-Receives-FDA-Emergency-Use-Authorization-for-its-COVID-19-IgM-Antibody-Blood-Test
There are a variety of different tests being deployed and a whole ecosystem is needed to support testing in different healthcare settings.
Our m2000 and Alinity m molecular systems are used in hospital and lab settings that are testing high volumes. ID NOW is a lightweight and portable instrument (the size of a toaster), that allows testing to occur near the patient to get rapid molecular results – including physicians' offices, urgent care settings, and hospital emergency departments.
BinaxNOW is also a rapid test. It can be used at home, by healthcare professionals at the point-of-care and or at home using a virtually guided service for the detection of antigens that form in the early stage of active infections. The test is highly portable (about the size of a credit card), affordable, and provides accurate results in 15 minutes.
Our lab serology blood tests running on ARCHITECT and Alinity i systems are used for the detection of antibodies, IgG and IgM, and to identify if a person was previously infected with the virus that causes COVID-19. An antibody is a protein that the body produces in the late stages of infection.
Antigen tests detect proteins of the SARS-CoV-2 virus that form during the infection cycle and indicate that a person has an active infection. Rapid antigen tests offer several important benefits. They are highly portable, scalable, easy-to-use and provide a flexible approach to helping more people in more places get access to reliable testing in a cost effective way. They are best at detecting when people are most infectious, so they know to stay home and isolate, minimizing the spread of COVID-19.
Antibody testing is an important step to tell if someone has been previously infected. It will provide a better understanding of the virus, including how long antibodies stay in the body. This type of knowledge could help support research about how the virus spreads within communities and immune responses to vaccines.
Abbott has been a global leader in infectious disease testing for decades, having developed the world's first HIV test. We created a Global Surveillance Program 25 years ago to monitor HIV and hepatitis viruses and have a long-standing discovery program to identify new or unknown pathogens. While developing an accurate and reliable test normally takes years, our expert team of scientists worked around the clock to compress the timeframe down to weeks. Our tests are all important tools in the broader comprehensive testing effort.
Molecular testing: Take a look at this infographic on how coronavirus molecular testing works. This how-to video also helps explain how molecular point-of-care testing on ID NOW works.
Serology testing: For more information on how testing for antibodies works, check out this infographic.
Antigen testing: For more information on how antigen testing works, check out this article.
Molecular tests that run on our m2000 system are already located in hospital and academic medical center labs, and reference laboratories, where patients are presenting for care. This allows for fast test results since they don’t need to be sent out. The systems have the ability to run high volumes of up to 470 tests in 24 hours, helping to meet the increasing demand for testing. Learn more about m2000 here: https://abbo.tt/3b8bASF
Alinity m systems have the ability to run high volumes of up to 1,080 tests in 24 hours, helping to meet the increasing demand for testing. Learn more about Alinity m here: https://abbo.tt/2zrt52N
ID NOW delivers positive results in as little as 5 minutes and negative results in 13 minutes. Learn more about COVID-19 testing on ID NOW here: https://abbo.tt/3KI9smQ
BinaxNOW provides results in 15 minutes. Learn more about COVID-19 testing on BinaxNOW here: https://abbo.tt/3hZPfNx
Our serology tests on the ARCHITECT and Alinity i systems can run up to 100-200 tests per hour. Learn more about ARCHITECT here: https://abbo.tt/3abd0eq
Learn more about Alinity i here: https://abbo.tt/2SWCvtU
We have always made highly reliable and accurate tests for other infectious diseases such as HIV and hepatitis, and we're highly confident in our tests since we’ve used the same approach to development. All of our tests met all testing criteria under the FDA's emergency use authorization (EUA) and we're continuing to collect more data in the field.
Since the start of the pandemic, Abbott has produced and shipped more than 2 billion COVID-19 tests. We continue to work closely with our customers around the world to bring testing to where it’s needed most.
Our antibody and molecular lab tests are available around the world, as well as our ID NOW rapid molecular test. For our rapid antigen tests, BinaxNOW is available in the U.S. and Panbio is available in many countries outside of the U.S.
Most of our tests may be available through your healthcare provider or at retail pharmacies. Our BinaxNOW Home Test is available through digital health provider, eMed and our BinaxNOW Self Test is available over-the-counter online and in retail stores including CVS, Walgreens and Walmart.
If you're with a hospital, lab or healthcare provider, please see the contact details below.
For general questions about BinaxNOW COVID-19 Ag Card: https://abbo.tt/2Qk76jp
For general questions about ID NOW: https://abbo.tt/2P8bYru
For general questions about m2000: https://abbo.tt/3fcjz2P
For general questions about ARCHITECT: https://abbo.tt/2X4m9RZ
For general questions about Alinity i: https://abbo.tt/335jaN6
For general questions about Alinity m: https://abbo.tt/2X754XS
Yes. Data transmitted in the app is encrypted and users only share name, birthdate, phone number, zip code and email address which is used for creating your personal profile in the app.
BinaxNOW COVID-19 Self Tests are available at major U.S. food, drug and mass merchandiser retailers across the country. It can also be performed at home using a virtually guided service in partnership with eMed™. Select CVS and Walgreens are using ID NOW in drive-thru settings in the U.S. You can find ID NOW in your local area here, and BinaxNOW COVID-19 Self Tests in retailers near you here.
The FDA has made tests available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Services' declaration that circumstances exist to justify the development of in vitro diagnostics (IVDs) under EUA for the detection and/or diagnosis of 2019-nCoV. Click here for more info: https://abbo.tt/2X7xwZo
Please check the CDC resources on how to protect yourself and what to do if you think you are sick: https://abbo.tt/3hJSINd
Learn more about Abbott's approach to tackling the coronavirus: https://abbo.tt/2WHMDco Read more about ARCHITECT: https://abbo.tt/3abd0eq Read more about ID NOW: https://abbo.tt/3KI9smQ Read more about m2000: https://abbo.tt/2U1WMiU Read more about Alinity i: https://abbo.tt/2SWCvtU Read more about Alinity m: https://abbo.tt/2zrt52N Read more about BinaxNOW COVID-19 Ag Card: https://abbo.tt/3hZPfNx
These tests have not been FDA cleared or approved. These tests have been authorized by FDA under EUAs for use by authorized laboratories and have been authorized only for the detection of nucleic acid from SARS-CoV-2 or detection of IgG antibodies against SARS-CoV-2, and not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.